DU 86

Drug Profile

DU 86

Alternative Names: DU-86

Latest Information Update: 13 Oct 2006

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Antineoplastics; Pyrroles
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 13 Oct 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
  • 17 Aug 2001 No-Development-Reported for Cancer in Japan (Unknown route)
  • 10 May 1995 Preclinical development for Cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top